1620 Investment Advisors, Inc. Biomarin Pharmaceutical Inc Transaction History
1620 Investment Advisors, Inc.
- $133 Million
- Q2 2025
A detailed history of 1620 Investment Advisors, Inc. transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, 1620 Investment Advisors, Inc. holds 503 shares of BMRN stock, worth $28,836. This represents 0.02% of its overall portfolio holdings.
Number of Shares
503
Previous 1,428
64.78%
Holding current value
$28,836
Previous $100,000
73.0%
% of portfolio
0.02%
Previous 0.08%
Shares
5 transactions
Others Institutions Holding BMRN
# of Institutions
668Shares Held
187MCall Options Held
1.25MPut Options Held
992K-
Black Rock Inc. New York, NY22.7MShares$1.3 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA19MShares$1.09 Billion0.03% of portfolio
-
Primecap Management CO Pasadena, CA17.8MShares$1.02 Billion1.06% of portfolio
-
Dodge & Cox San Francisco, CA15MShares$857 Million0.65% of portfolio
-
Viking Global Investors LP10.8MShares$619 Million2.55% of portfolio
About BIOMARIN PHARMACEUTICAL INC
- Ticker BMRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,824,000
- Market Cap $10.7B
- Description
- BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...